[1] |
WHO. The end TB strategy: WHO; 2014. |
[2] |
Wang L, Zhang H, Ruan Y, et al. Tuberculosis prevalence in China, 1990-2010: a longitudinal analysis of national survey data. Lancet, 2014; 383, 2057−64. doi: 10.1016/S0140-6736(13)62639-2 |
[3] |
Uplekar M, Weil D, Lonnroth K, et al. WHO's new end TB strategy. Lancet, 2015; 385, 1799−801. doi: 10.1016/S0140-6736(15)60570-0 |
[4] |
WHO. The end TB strategy: WHO; 2014. |
[5] |
MOH, CCDC. China national tuberculosis program. Beijing: Peking Union Medical College press; 2008. (In Chinese) |
[6] |
Li Y, Zheng Y, Lu L, et al. Acceptance of chemo-prophylaxis for latent tuberculosis infection among high school/college student contacts of tuberculosis patients in Shanghai, China. Biomed Environ Sci, 2018; 31, 317−21. |
[7] |
Li SM, Hou PBo, Qu XJ, et al. Investigation and analysis of a tuberculosis epidemic in a university. Pract J Med Pharm, 2016; 33, 64−5. |
[8] |
Sañé Schepisi M, Motta I, Dore S, et al. Tuberculosis transmission among children and adolescents in schools and other congregate settings: a systematic review. New Microbiol, 2019; 41, 282−90. |
[9] |
Lee HS, Kee SJ, Shin JH, et al. Xpert MTB/rif assay as a substitute for smear microscopy in an intermediate-burden setting. Am J Respir Crit Care Med, 2019; 199, 784−94. doi: 10.1164/rccm.201804-0654OC |